Pharmacology/Pharmaceutical Industry
[Abstract Only] Randomized Trial: Fenfluramine Hydrochloride for the Treatment of Seizures in Dravet Syndrome
23 Jan, 2020 | 01:49h | UTCFenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial – The Lancet (link to abstract – $ for full-text)
Commentaries: Drug could reduce frequency of seizures for children with Dravet Syndrome – The Lancet (free) AND Old drug offers new hope for children with devastating disorder – World Pharma News (free)
[Abstract Only] Randomized Trial: Cabazitaxel vs. Abiraterone or Enzalutamide in Metastatic Prostate Cancer
23 Jan, 2020 | 01:48h | UTCCabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: ESMO 2019: Cabazitaxel vs Abiraterone or Enzalutamide in Previously Treated Metastatic Castration-Resistant Prostate Cancer – The ASCO Post (free)
Related Commentary on Twitter
#VisualAbstract: Cabazitaxel in Metastatic Prostate Cancer. See more NEJM Visual Abstracts now: pic.twitter.com/nUeb6dqRYi
— NEJM (@NEJM) December 26, 2019
[Abstract Only] Systematic Review: No Benefit from Flexible Titration Above Minimum Licensed Dose in Prescribing Antidepressants for Major Depression
22 Jan, 2020 | 09:27h | UTCNo benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review – Acta Psychiatrica Scandinavica (link to abstract – $ for full-text)
Related Meta-analysis: Optimal Dose of Antidepressants in Major Depression – The Lancet Psychiatry (free study and commentaries)
Cohort Study: Second-generation Antipsychotics and Pregnancy Complications
22 Jan, 2020 | 09:18h | UTC
Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment
22 Jan, 2020 | 09:15h | UTCRelated: Cardiotoxicity of immune checkpoint inhibitors – ESMO Open (free) AND Cardiotoxicity from immune checkpoint inhibitors – IJC Heart & Vasculature (free) AND Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology – Journal of the Formosan Medical Association (free) AND Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock – JACC: CardioOncology (free)
[Abstract Only] Randomized Trial: Effects of Addition of Anti-thymocyte Globulin to Standard Graft-versus-host Disease Prophylaxis in Patients with Hematological Malignancies Undergoing Transplantation from Unrelated Donor
22 Jan, 2020 | 09:16h | UTCAddition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial – The Lancet Haematology (link to abstract – $ for full-text)
Randomized Trial: Efficacy of Glecaprevir and Pibrentasvir in Patients with Chronic HCV Genotype 1 Patients After Treatment Failure with NS5A Inhibitor Plus Sofosbuvir Therapy
22 Jan, 2020 | 09:11h | UTCEditorial: Retreatment Options for Patients Who Failed Direct-Acting Antiviral Regimens Containing NS5A Inhibitors: Is Glecaprevir/Pibrentasvir a Valid and Robust Option? (free)
Source: EvidenceAlerts
Related Commentary on Twitter
16 weeks treatment with G/P produced sustained virologic response 12 weeks after treatment in >90% of chronic #HCV genotype 1 patients https://t.co/YGM81urXpm pic.twitter.com/g1OtzeKQsL
— Gastroenterology (@AGA_Gastro) November 27, 2019
[Abstract Only] Randomized Trial: Effectiveness of Mirtazapine as Add-on to Paroxetine vs. Paroxetine or Mirtazapine Monotherapy in Patients with Depression with Early Non-response to Paroxetine
22 Jan, 2020 | 09:08h | UTCEffectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial – Psychological Medicine (link to abstract – $ for full-text)
[Abstract Only] Randomized Trial: Satralizumab for Neuromyelitis Optica Spectrum Disorder
21 Jan, 2020 | 01:05h | UTCTrial of Satralizumab in Neuromyelitis Optica Spectrum Disorder – New England Journal of Medicine (link to abstract – $ for full-text)
The PEPTIC Randomized Clinical Trial: Similar Outcomes with Stress Ulcer Prophylaxis with Proton Pump Inhibitors vs. Histamine-2 Receptor Blockers Among ICU Patients Receiving Invasive Mechanical Ventilation
19 Jan, 2020 | 21:42h | UTCEditorial: Proton Pump Inhibitors vs Histamine-2 Receptor Blockers for Stress Ulcer Prophylaxis in Critically Ill Patients: Issues of Interpretability in Pragmatic Trials (free for a limited period)
Conference Presentation: Effect of Stress Ulcer Prophylaxis With PPIs vs H2RBs on Mortality in Ventilated ICU Patients (free)
Commentaries: JC: The PEPTIC study PPI vs H2RBs on the ICU – St Emlyn’s (free) AND Risks And Benefits Of Proton Pump Inhibitors To Prevent Gi Bleeds In Intensive Care Patients – MedicalResearch.com (free)
A Review of Cancer Immunotherapy Toxicity
19 Jan, 2020 | 21:38h | UTCA review of cancer immunotherapy toxicity – CA: A Cancer Journal for Clinicians (free)
Related: Immune Checkpoint Inhibitor Toxicities (free guidelines and reviews on the subject)
3-year Follow-up of the SCOT RCT: 3-month Oxaliplatin-containing Adjuvant Chemotherapy is Non-inferior to 6 Months of the Same Regimen for Patients with High-risk Stage II and III Colorectal Cancer
19 Jan, 2020 | 21:28h | UTCOriginal Article: 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial – The Lancet Oncology (free)
Source: EvidenceAlerts
Perspective: Are Polypills and Population-based Treatment the Next Big Things?
19 Jan, 2020 | 20:53h | UTCAre polypills and population-based treatment the next big things? – Harvard Health Blog (free)
Related: Randomized Trial: Polypill for Cardiovascular Disease Prevention in an Underserved Population (randomized trials, commentaries and guideline on the subject)
[Abstract Only] Randomized Trial: Different Doses of Adjuvant Ipilimumab vs. High-Dose Interferon Alfa-2b in Patients with Resected High-Risk Melanoma
19 Jan, 2020 | 20:40h | UTCOriginal Study: Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609 – Journal of Clinical Oncology (link to abstract – $ for full-text)
[Abstract Only] Randomized Trial: Anifrolumab in Active Systemic Lupus Erythematosus
17 Jan, 2020 | 09:39h | UTCTrial of Anifrolumab in Active Systemic Lupus Erythematosus – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: TULIP2 – Anifrolumab Succeeds in Lupus – RheumNow (free)
Randomized Trial: Twice-daily vs. Alternate-day Oral Iron Therapy in the Treatment of Iron-deficiency Anemia
16 Jan, 2020 | 03:23h | UTC
The use of Antidepressants in Oncology: A Review and Practical Tips for Oncologists
16 Jan, 2020 | 02:39h | UTC
[Abstract Only] Randomized Trial: Ixekizumab for Patients with Non-radiographic Axial Spondyloarthritis
16 Jan, 2020 | 02:29h | UTCIxekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial – The Lancet (link to abstract – $ for full-text)
Commentary: #VisualAbstract: Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X) – 2 Minute Medicine (free)
https://twitter.com/TheLancet/status/1214872375822553088
FDA Safety Communication: Possible Increased Risk of Cancer with Weight-loss Medicine Lorcaserin
15 Jan, 2020 | 08:02h | UTCCommentaries: CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA – TCTMD (free) AND FDA Warning: Weight Loss Drug Belviq May Increase Cancer Risk- Forbes (free)
BMJ Collection: Achieving Fair Pricing of Medicines
14 Jan, 2020 | 00:45h | UTCHomepage: Achieving fair pricing of medicines – The BMJ (free articles)
Editorial: Can affordability and innovation coexist for medicines?
– Defining the concept of fair pricing for medicines
– Strategies to achieve fairer prices for generic and biosimilar medicines
– Pricing of pharmaceuticals is becoming a major challenge for health systems
– Price transparency is a step towards sustainable access in middle income countries
Randomized Trial: Efficacy and Safety of Lumateperone for Treatment of Schizophrenia
14 Jan, 2020 | 00:34h | UTCEditorial: The Potential Role of Lumateperone—Something Borrowed? Something New? – JAMA Psychiatry (free for a limited period)
Related Commentary on Twitter
In a Phase 3 trial, lumateperone (42mg) demonstrated significant efficacy for improving the symptoms of schizophrenia with a favorable safety profile. https://t.co/0eukuf1Qrf
— JAMA Psychiatry (@JAMAPsych) January 8, 2020
[Abstract Only] Meta-Analysis: Opioids Not Beneficial for Chronic Osteoarthritis Pain
14 Jan, 2020 | 00:23h | UTCOpioids for chronic osteoarthritis pain. An updated systematic review and meta‐analysis of efficacy, tolerability and safety in randomized placebo‐controlled studies of at least four weeks double‐blind duration – European Journal of Pain (link to abstract – $ for full-text)
Related Systematic Review: Oral or transdermal opioids for osteoarthritis of the knee or hip – Cochrane Library (free)
Perspective: FDA and NIH Let Clinical Trial Sponsors Keep Results Secret and Break the Law
14 Jan, 2020 | 00:21h | UTCFDA and NIH let clinical trial sponsors keep results secret and break the law – Science (a few articles per month are free)
Related Commentary on Twitter
Shameful lack, non-compliance of reporting of clinical trials by academic medical centershttps://t.co/dmbSeUNJur #openaccess@sciencemagazine by @cpiller
comparison with industry striking pic.twitter.com/5aXMIvjGvQ— Eric Topol (@EricTopol) January 13, 2020
[Abstract Only] Randomized Trial: Adding Acetaminophen to Ibuprofen Does Not Improve Symptoms in Acute Low Back Pain
14 Jan, 2020 | 00:12h | UTCIbuprofen Plus Acetaminophen Versus Ibuprofen Alone for Acute Low Back Pain: An Emergency Department–based Randomized Study – Academic Emergency Medicine (link to abstract – $ for full-text)
Commentary: RCT – Ibuprofen + Acetaminophen for Low Back Pain – JournalFeed (free)
Related: Paracetamol for low back pain – Cochrane Library (free)
Review: New Oral Anti-Cancer Drugs and Medication Safety
14 Jan, 2020 | 00:11h | UTCNew Oral Anti-Cancer Drugs and Medication Safety – Deutsches Ärzteblatt international (free)